Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 20, 2020 - Issue 3
Submit an article Journal homepage
353
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Francesco PantanoDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyView further author information
,
Marco RussanoDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyCorrespondence[email protected]
View further author information
,
Alfredo BerrutiDepartment of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, Brescia, ItalyView further author information
,
Giovanni MansuetoMedical Oncology Unit, ASL Frosinone, Frosinone, ItalyView further author information
,
Maria R. MigliorinoPulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, ItalyView further author information
,
Vincenzo AdamoMedical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina, Messina, ItalyView further author information
,
Giuseppe AprileDepartment of Oncology, University and General Hospital, Udine, Italy;Department of Oncology, San Bortolo General Hospital, ULSS8 Berica, Vicenza, ItalyView further author information
,
Alain GelibterMedical Oncology Unit, Policlinico Umberto I, Rome, ItalyView further author information
,
Corrado FicorellaMedical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy;Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyView further author information
,
Alfredo FalconeUnit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, ItalyView further author information
,
Antonio RussoSection of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, ItalyView further author information
,
Michele AietaDivision of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero, Vulture, ItalyView further author information
,
Michele MaioDepartment of Oncology, Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, ItalyView further author information
,
Olga MartelliMedical Oncology Unit, Azienda Ospedale San Giovanni Addolorata, Roma, ItalyView further author information
,
Sandro BarniDivision of Oncology, Azienda Ospedaliera Treviglio, Treviglio, ItalyView further author information
,
Andrea NapolitanoDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyView further author information
,
Elisa RocaDepartment of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, Brescia, ItalyView further author information
,
Silvia QuadriniMedical Oncology Unit, ASL Frosinone, Frosinone, ItalyView further author information
,
Daniela IaconoPulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, ItalyView further author information
,
Alessandro RussoMedical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina, Messina, ItalyView further author information
,
Lorenzo CalvettiDepartment of Oncology, University and General Hospital, Udine, Italy;Department of Oncology, San Bortolo General Hospital, ULSS8 Berica, Vicenza, ItalyView further author information
,
Mario A. OcchipintiMedical Oncology Unit, Policlinico Umberto I, Rome, ItalyView further author information
,
Alessio CortelliniMedical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy;Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyORCID Iconhttps://orcid.org/0000-0002-1209-5735View further author information
ORCID Icon,
Enrico VasileUnit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, ItalyView further author information
,
Francesco PassigliaSection of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, ItalyView further author information
,
Marco ImperatoriDivision of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero, Vulture, ItalyView further author information
,
Luana CalabròDepartment of Oncology, Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, ItalyView further author information
,
Anna M. Di GiacomoDepartment of Oncology, Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, ItalyView further author information
,
Fausto PetrelliDivision of Oncology, Azienda Ospedaliera Treviglio, Treviglio, ItalyView further author information
,
Giulia PasquiniUnit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, ItalyView further author information
,
Tindara FranchinaMedical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina, Messina, ItalyView further author information
,
Olga VendittiMedical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy;Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyView further author information
,
Salvatore IntagliataDepartment of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, Brescia, ItalyView further author information
,
Antonio GalvanoSection of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, ItalyView further author information
,
Iacopo FioroniDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyView further author information
,
Bruno VincenziDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyView further author information
,
Giuseppe ToniniDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyView further author information
&
Daniele SantiniDepartment of Medical Oncology, University Campus Bio-Medico, Rome, ItalyView further author information
 show all
Pages 319-326 | Received 29 Jul 2019, Accepted 29 Jan 2020, Published online: 06 Feb 2020

References

  • Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
  • Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2017 Jan;22(1):81–88.
  • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123.
  • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627.
  • Brahmer JR, Horn L, Jackman D, et al. Five-year follow-up from the CA209-003 study of Nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors. Presented at: 2017 AACR Annual Meeting; April 1–5, 2017; Washington, DC. Abstract CT077.
  • Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase ii and phase iii trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015 Jun 10;33(17):1889–1894.
  • Topalian SL1, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanomareceiving Nivolumab. J Clin Oncol. 2014 Apr 1;32(10):1020–1030.
  • Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–1833.
  • Herbst RS1, Baas P2, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controller trial. Lancet. 2016 Apr 9;387(10027):1540–1550.
  • Teng F, Meng X, Kong L, et al. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review. Cancer Lett. 2018 Feb 1;414: 166–173.
  • Chae YK, Pan A, Davis AA, et al. Biomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung cancer: is PD-L1Expression a good marker for patient selection? Clin Lung Cancer. 2016 Sep;17(5):350–361.
  • Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093–2104.
  • Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078–2092.
  • Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
  • Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35:1–39.
  • Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with Nivolumab. Lung Cancer. 2018;115:71–74.
  • Tereatoka S, Fujimoto D, Morimoto T, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with Nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12(12):1798–1805.
  • Elias R, Giobbie-Hurder A, McCleary NJ. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018;6:26.
  • Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37.
  • Morgensztern D1, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012 Oct;7(10):1485–1489.
  • Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res. 1997 Jan;3(1):47–50.
  • DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005;4(3):342–346.
  • Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 2012;4(4):376–389.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.